Initial experience using rapamycin immunosuppression in pediatric intestinal transplant recipients.
Horslen
S
S
Pediatric GI, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA.
Torres
C
C
Collier
D
D
Iyer
K
K
Sudan
D
D
Shaw
B
B
Langas
A
A
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007422:Intestines / Q000637:transplantation*; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D007677:Kidney Function Tests; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D014184:Transplantation, Homologous / Q000276:immunology / Q000502:physiology*
D007166:Immunosuppressive Agents; D020123:Sirolimus